Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior ...

Virtual AI-informed immunocyte profiling (VAIP) from H&E as a predictor of multi-cancer prognosis. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include ...